Drug interactions between Prolia and Reclast
|Reclast (zoledronic acid)|
Interactions between your drugs
zoledronic acid ↔ denosumab
Applies to:Reclast (zoledronic acid) and Prolia (denosumab)
Both denosumab and zoledronic acid can cause a rare but serious condition known as osteonecrosis of the jaw (ONJ), and combining these medications may increase the risk. ONJ is the exposure of jaw bone through the gums associated with death of bone tissue and usually occurs after invasive dental procedures such as tooth extraction. Severe cases may require surgery. The risk is generally related to the dose of these medications and the duration of treatment. Because zoledronic acid can remain in the bone for years, the risk may exist for some time even after you have stopped taking it. Good oral hygiene and regular dental care is the best way to lower the risk of ONJ. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek medical attention if you experience potential signs and symptoms of ONJ such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw. Also, before you get any type of dental surgery, be sure to let your care provider know you are taking these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Bone resorption inhibitors
The recommended maximum number of medicines in the 'bone resorption inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'bone resorption inhibitors' category:
- denosumab (active ingredient in Prolia (denosumab))
- zoledronic acid (active ingredient in Reclast (zoledronic acid))
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.